1 hr. ago
Moderna (MRNA) surged 177% and Merck (MRK) rose 12.5% after their mRNA cancer vaccine met key Phase 3 melanoma trial goals.
Phase 2b data showed a 49% reduction in recurrence or death versus Keytruda alone, with nine studies now underway across multiple cancer types.
Act now: the ******* yst who called NVIDIA in 2010 just named his top 10 AI stocks — and Merck didn't make the cut. Grab the names FREE today.
Moderna (NASDAQ:MRNA) shares have crashed 20% as of 12:00 PM ET on Thursday after delivering one of the biotech sector's most extraordinary single-day moves of 2026. CNBC co-anchor Andrew Ross Sorkin told viewers that Moderna's Phase 3 results for its experimental cancer vaccine sent the stock soaring 177% on Wednesday, while partner Merck (NYSE:MRK) rallied 12.5%.
As Sorkin summarized on air, "The mRNA based shot, in combination with Merck's immunotherapy called Keytruda, met key goals in a trial of patients with higher risk or advanced melanoma whose detectable cancer had been removed."
#mrna #merck #phase #sorkin
Phase 2b data showed a 49% reduction in recurrence or death versus Keytruda alone, with nine studies now underway across multiple cancer types.
Act now: the ******* yst who called NVIDIA in 2010 just named his top 10 AI stocks — and Merck didn't make the cut. Grab the names FREE today.
Moderna (NASDAQ:MRNA) shares have crashed 20% as of 12:00 PM ET on Thursday after delivering one of the biotech sector's most extraordinary single-day moves of 2026. CNBC co-anchor Andrew Ross Sorkin told viewers that Moderna's Phase 3 results for its experimental cancer vaccine sent the stock soaring 177% on Wednesday, while partner Merck (NYSE:MRK) rallied 12.5%.
As Sorkin summarized on air, "The mRNA based shot, in combination with Merck's immunotherapy called Keytruda, met key goals in a trial of patients with higher risk or advanced melanoma whose detectable cancer had been removed."
#mrna #merck #phase #sorkin
3 hours ago
It's the day after one of the surprise healthcare stories of 2026.
Moderna (MRNA) shares fell 20% in early trading on Thursday after a stunning 177% gain yesterday on news that the biotech and partner Merck (MRK) notched a big breakthrough in the fight against cancer.
The pair announced that their personalized mRNA cancer vaccine — called intismeran — successfully hit its primary goal in a Phase 3 late-stage trial, demonstrating a meaningful reduction in melanoma recurrence in patients who had already had their tumors surgically removed.
The trial compared using intismeran alongside Merck's well-known immunotherapy drug Keytruda against using Keytruda alone. Patients who received the combination lived meaningfully longer without their cancer returning or spreading.
"It's a home run, maybe even a grand slam," Dr. Ezekiel Emanuel said on Yahoo Finance (video above). "The results are pretty amazing."
#patients
Moderna (MRNA) shares fell 20% in early trading on Thursday after a stunning 177% gain yesterday on news that the biotech and partner Merck (MRK) notched a big breakthrough in the fight against cancer.
The pair announced that their personalized mRNA cancer vaccine — called intismeran — successfully hit its primary goal in a Phase 3 late-stage trial, demonstrating a meaningful reduction in melanoma recurrence in patients who had already had their tumors surgically removed.
The trial compared using intismeran alongside Merck's well-known immunotherapy drug Keytruda against using Keytruda alone. Patients who received the combination lived meaningfully longer without their cancer returning or spreading.
"It's a home run, maybe even a grand slam," Dr. Ezekiel Emanuel said on Yahoo Finance (video above). "The results are pretty amazing."
#patients
8 days ago
(NewsNation) — A former director of the U.S. Centers for Disease Control and Prevention faults the federal government for recommending that pregnant women take mRNA vaccines during the COVID pandemic.
Dr. Robert Redfield, who headed the CDC during the pandemic, joined "Katie Pavlich Tonight" to comment on revived discussion about whether the vaccine can cause miscarriages in women early in their pregnancy.
He said he hasn't seen data establishing a link but said it made no sense to recommend the vaccine to expectant mothers.
Breaking down Republican accusations against Anthony Fauci
"I never thought we should vaccinate pregnant women. I was not in favor of that policy recommendation because the COVID vaccine did not prevent infection," Redfield said Tuesday.
#vaccine #pandemic
Dr. Robert Redfield, who headed the CDC during the pandemic, joined "Katie Pavlich Tonight" to comment on revived discussion about whether the vaccine can cause miscarriages in women early in their pregnancy.
He said he hasn't seen data establishing a link but said it made no sense to recommend the vaccine to expectant mothers.
Breaking down Republican accusations against Anthony Fauci
"I never thought we should vaccinate pregnant women. I was not in favor of that policy recommendation because the COVID vaccine did not prevent infection," Redfield said Tuesday.
#vaccine #pandemic
8 days ago
During the August 6 episode of CNBC's Mad Money, Jim Cramer pointed to a growing sector rotation as portfolio managers look for innovation outside the mega-cap technology ***** e. He said:
Finally, tech had such a run that portfolio managers want exposure to other sectors of the market that still have innovation. Think of them as non- tech tech stocks. For the… Charitable Trust club, we've been emphasizing Eli Lilly and Johnson & Johnson. And we talked about these… I talked about them at length with Jeff Marks today at our 10:20 call. They both had terrific quarters and deserve to be bought on any weakness.
Cramer's thesis highlights how mega-cap healthcare operators provide defensive shelter with strong dividend profiles and maintain high-growth product pipelines. Cramer further emphasized that innovation in biotechnology is driving tangible financial gains. He said:
Amgen just racked up an excellent quarter. And credit where credit's due, time to accept that Moderna has begun to realize its stream of specialized vaccines for specific illnesses. Just last night, the company, it received FDA approval for its mRNA flu vaccine. Well, there's a reason why the stock's up 83% for the year.
Later in the August 6 episode, a caller asked Cramer about Bristol-Myers Squibb Company (NYSE:BMY) after holding the stock through recent buyout speculation. In response, Cramer remarked:
#episode #managers
Finally, tech had such a run that portfolio managers want exposure to other sectors of the market that still have innovation. Think of them as non- tech tech stocks. For the… Charitable Trust club, we've been emphasizing Eli Lilly and Johnson & Johnson. And we talked about these… I talked about them at length with Jeff Marks today at our 10:20 call. They both had terrific quarters and deserve to be bought on any weakness.
Cramer's thesis highlights how mega-cap healthcare operators provide defensive shelter with strong dividend profiles and maintain high-growth product pipelines. Cramer further emphasized that innovation in biotechnology is driving tangible financial gains. He said:
Amgen just racked up an excellent quarter. And credit where credit's due, time to accept that Moderna has begun to realize its stream of specialized vaccines for specific illnesses. Just last night, the company, it received FDA approval for its mRNA flu vaccine. Well, there's a reason why the stock's up 83% for the year.
Later in the August 6 episode, a caller asked Cramer about Bristol-Myers Squibb Company (NYSE:BMY) after holding the stock through recent buyout speculation. In response, Cramer remarked:
#episode #managers
15 days ago
Pfizer has upgraded the bottom-end of its full-year (FY) revenue outlook by $500m as performance from the drugmaker's lead products more than compensated for weaker Covid-19-related sales.
Pfizer now expects 2026 revenue to land between $60.5bn and $62.5bn, up from the $59.5bn to $62.5bn range it previously forecast.
According to the big pharma company, the revised outlook reflects a $1.5bn better-than-expected performance from its non-Covid products. Sales for Covid-19 products, which include antiviral Paxlovid and mRNA vaccine Comirnaty, are conversely expected to bring in $1bn less. The former's sales were down 95% in Q2, while the latter dropped 34%.
Pfizer emerged as a pharmaceutical powerhouse during the pandemic, but lower infection rates and narrower use cases mean its Covid-19 brands are impacting the company's bottom line.
Pfizer still recorded revenues of $15bn in Q2, up 3% from the same quarter in 2025, meaning its non-Covid products more than offset headwinds. This figure beat consensus estimates, as per Citi ******* ysts.
#covid #sales #bottom #performance
Pfizer now expects 2026 revenue to land between $60.5bn and $62.5bn, up from the $59.5bn to $62.5bn range it previously forecast.
According to the big pharma company, the revised outlook reflects a $1.5bn better-than-expected performance from its non-Covid products. Sales for Covid-19 products, which include antiviral Paxlovid and mRNA vaccine Comirnaty, are conversely expected to bring in $1bn less. The former's sales were down 95% in Q2, while the latter dropped 34%.
Pfizer emerged as a pharmaceutical powerhouse during the pandemic, but lower infection rates and narrower use cases mean its Covid-19 brands are impacting the company's bottom line.
Pfizer still recorded revenues of $15bn in Q2, up 3% from the same quarter in 2025, meaning its non-Covid products more than offset headwinds. This figure beat consensus estimates, as per Citi ******* ysts.
#covid #sales #bottom #performance
1 month ago
Moderna, Inc. (NASDAQ:MRNA) is one of the 10 Best Performing American Stocks in June 2026.
On July 7, 2026, RBC Capital raised the firm's price target on Moderna, Inc. (NASDAQ:MRNA) to $45 from $38 and kept a Sector Perform rating on the shares as part of a broader Q2 earnings preview for biotech. RBC said the biotech sector has gained considerable momentum, helped by strong data expanding innovative ***** es and perceptions of improving FDA flexibility and stability. The firm added that Q2 earnings are shaping up to be seasonally strong, with multiple opportunities for beats and continued M&A activity.
On June 26, Piper Sandler raised the firm's price target on Moderna, Inc. (NASDAQ:MRNA) to $77 from $69 previously and kept an Overweight rating on the shares.
Copyright: nexusplexus / 123RF Stock Photo
On June 25, Moderna announced research and early development updates at its Science Day event. The company said it is balancing near-term growth with long-term innovation, supported by its four approved products, infectious disease launches, geographic expansion, and late-stage pipeline opportunities, including investigational intismeran autogene therapy and propionic acidemia therapeutic. Moderna also said its Scientific Intelligence Engine uses data, AI, and machine learning, automation, and robotics to accelerate discovery and improve operations.
On July 7, 2026, RBC Capital raised the firm's price target on Moderna, Inc. (NASDAQ:MRNA) to $45 from $38 and kept a Sector Perform rating on the shares as part of a broader Q2 earnings preview for biotech. RBC said the biotech sector has gained considerable momentum, helped by strong data expanding innovative ***** es and perceptions of improving FDA flexibility and stability. The firm added that Q2 earnings are shaping up to be seasonally strong, with multiple opportunities for beats and continued M&A activity.
On June 26, Piper Sandler raised the firm's price target on Moderna, Inc. (NASDAQ:MRNA) to $77 from $69 previously and kept an Overweight rating on the shares.
Copyright: nexusplexus / 123RF Stock Photo
On June 25, Moderna announced research and early development updates at its Science Day event. The company said it is balancing near-term growth with long-term innovation, supported by its four approved products, infectious disease launches, geographic expansion, and late-stage pipeline opportunities, including investigational intismeran autogene therapy and propionic acidemia therapeutic. Moderna also said its Scientific Intelligence Engine uses data, AI, and machine learning, automation, and robotics to accelerate discovery and improve operations.
2 months ago
Moderna, Inc. (NASDAQ:MRNA) was among the stocks Jim Cramer commented on as he advised investors on how to take advantage of Wednesday's market rotation. Cramer highlighted the stock's significant gains during the year, as he said:
If you look at the market's best performers year to date, nearly all of them are either companies that sell hardware into the data center or companies that sell hardware to the hardware makers. But there's one solitary exception in the top 15: Moderna, the biotech company best known for its COVID vaccine. Right now, Moderna's the 12th best-performing stock in the S&P 500, up 146% year to date. Now, that is pretty impressive… The truth is, after spending years lost in the post-COVID wilderness, this company's now got a lot going for it. I think the rally's for real. I think the company's for real now…
It's no wonder that Moderna stock has caught fire; think about all these great things they're doing. For the first time in a long time, the company seems like it is something to get excited about in the not too distant future. But, and this is a big but, let's not forget that Moderna's still losing money. In fact, they don't expect to reach cash break-even levels until 2028. Actual earnings per share likely won't turn positive until 2029. But the company is at last beginning to realize its true potential. Plus, while I found Moderna's cancer trials very impressive, these are basically just cancer treatments. They're not the personalized anti-cancer vaccines that management's been talking about for years that got me so excited about the stock…
Let me give you the bottom line on this amazing story that wasn't amazing for a long time: Even though Moderna's still early on its turnaround, it's hard not to be excited about what the company presented just last week. Moderna's got a plethora of thoughtful new products and a clear roadmap to profitability for the first time in such a long time. Honestly, now, look, I am a bit wary of chasing any stock that's up nearly 150%, but the truth is Moderna finally feels investible again. That said, I recommend waiting for a pullback, there probably will be one, before you buy. Take your time. I think Moderna's got a bright future, though. It'll take years to get there… For the first time in ages, I like having a position in Moderna.
Photo by Ian Hutchinson on Unsplash
If you look at the market's best performers year to date, nearly all of them are either companies that sell hardware into the data center or companies that sell hardware to the hardware makers. But there's one solitary exception in the top 15: Moderna, the biotech company best known for its COVID vaccine. Right now, Moderna's the 12th best-performing stock in the S&P 500, up 146% year to date. Now, that is pretty impressive… The truth is, after spending years lost in the post-COVID wilderness, this company's now got a lot going for it. I think the rally's for real. I think the company's for real now…
It's no wonder that Moderna stock has caught fire; think about all these great things they're doing. For the first time in a long time, the company seems like it is something to get excited about in the not too distant future. But, and this is a big but, let's not forget that Moderna's still losing money. In fact, they don't expect to reach cash break-even levels until 2028. Actual earnings per share likely won't turn positive until 2029. But the company is at last beginning to realize its true potential. Plus, while I found Moderna's cancer trials very impressive, these are basically just cancer treatments. They're not the personalized anti-cancer vaccines that management's been talking about for years that got me so excited about the stock…
Let me give you the bottom line on this amazing story that wasn't amazing for a long time: Even though Moderna's still early on its turnaround, it's hard not to be excited about what the company presented just last week. Moderna's got a plethora of thoughtful new products and a clear roadmap to profitability for the first time in such a long time. Honestly, now, look, I am a bit wary of chasing any stock that's up nearly 150%, but the truth is Moderna finally feels investible again. That said, I recommend waiting for a pullback, there probably will be one, before you buy. Take your time. I think Moderna's got a bright future, though. It'll take years to get there… For the first time in ages, I like having a position in Moderna.
Photo by Ian Hutchinson on Unsplash
2 months ago
Moderna, Inc. (NASDAQ:MRNA) was among the stocks Jim Cramer commented on as he advised investors on how to take advantage of Wednesday's market rotation. Cramer highlighted the stock's significant gains during the year, as he said:
If you look at the market's best performers year to date, nearly all of them are either companies that sell hardware into the data center or companies that sell hardware to the hardware makers. But there's one solitary exception in the top 15: Moderna, the biotech company best known for its COVID vaccine. Right now, Moderna's the 12th best-performing stock in the S&P 500, up 146% year to date. Now, that is pretty impressive… The truth is, after spending years lost in the post-COVID wilderness, this company's now got a lot going for it. I think the rally's for real. I think the company's for real now…
It's no wonder that Moderna stock has caught fire; think about all these great things they're doing. For the first time in a long time, the company seems like it is something to get excited about in the not too distant future. But, and this is a big but, let's not forget that Moderna's still losing money. In fact, they don't expect to reach cash break-even levels until 2028. Actual earnings per share likely won't turn positive until 2029. But the company is at last beginning to realize its true potential. Plus, while I found Moderna's cancer trials very impressive, these are basically just cancer treatments. They're not the personalized anti-cancer vaccines that management's been talking about for years that got me so excited about the stock…
Let me give you the bottom line on this amazing story that wasn't amazing for a long time: Even though Moderna's still early on its turnaround, it's hard not to be excited about what the company presented just last week. Moderna's got a plethora of thoughtful new products and a clear roadmap to profitability for the first time in such a long time. Honestly, now, look, I am a bit wary of chasing any stock that's up nearly 150%, but the truth is Moderna finally feels investible again. That said, I recommend waiting for a pullback, there probably will be one, before you buy. Take your time. I think Moderna's got a bright future, though. It'll take years to get there… For the first time in ages, I like having a position in Moderna.
Photo by Ian Hutchinson on Unsplash
If you look at the market's best performers year to date, nearly all of them are either companies that sell hardware into the data center or companies that sell hardware to the hardware makers. But there's one solitary exception in the top 15: Moderna, the biotech company best known for its COVID vaccine. Right now, Moderna's the 12th best-performing stock in the S&P 500, up 146% year to date. Now, that is pretty impressive… The truth is, after spending years lost in the post-COVID wilderness, this company's now got a lot going for it. I think the rally's for real. I think the company's for real now…
It's no wonder that Moderna stock has caught fire; think about all these great things they're doing. For the first time in a long time, the company seems like it is something to get excited about in the not too distant future. But, and this is a big but, let's not forget that Moderna's still losing money. In fact, they don't expect to reach cash break-even levels until 2028. Actual earnings per share likely won't turn positive until 2029. But the company is at last beginning to realize its true potential. Plus, while I found Moderna's cancer trials very impressive, these are basically just cancer treatments. They're not the personalized anti-cancer vaccines that management's been talking about for years that got me so excited about the stock…
Let me give you the bottom line on this amazing story that wasn't amazing for a long time: Even though Moderna's still early on its turnaround, it's hard not to be excited about what the company presented just last week. Moderna's got a plethora of thoughtful new products and a clear roadmap to profitability for the first time in such a long time. Honestly, now, look, I am a bit wary of chasing any stock that's up nearly 150%, but the truth is Moderna finally feels investible again. That said, I recommend waiting for a pullback, there probably will be one, before you buy. Take your time. I think Moderna's got a bright future, though. It'll take years to get there… For the first time in ages, I like having a position in Moderna.
Photo by Ian Hutchinson on Unsplash
2 months ago
While artificial intelligence stocks had a whipsaw June, they've had a stellar 2026 so far. Memory giants Sandisk (SNDK), Micron Technology (MU), Western Digital (WDC) and Seagate Technology (STX) have more than tripled this year, along with fellow S&P 500 components Intel (INTC), Marvell Technology (MRVL) and Dell Technologies (DELL). All are AI stocks.
Indeed, some 22 S&P 500 stocks have doubled through June 30. All but one, Moderna (MRNA), is an AI play. Of the seven standouts, Intel and Marvell are arguably actionable. Dell and Western Digital stock are close to entries.
Even given that memory plays are leading a hot AI rally, Sandisk stock's performance is stunning, with a massive 857.8% gain through 2026. But that looks positively mild compared to Sandisk earnings growth of 644% and 7,903% in the last two quarters, with 11,500% seen for the just-ended June quarter.
Since hitting a record 2,354.39 on June 22, SNDK stock has whipsawed up and down, but continued to hold the 21-day line.
Micron stock has quadrupled this year, up 304.4%. Earnings have exploded 682% and 1,215% in the past two quarters, with the memory-chip giant last week guiding sharply higher.
Indeed, some 22 S&P 500 stocks have doubled through June 30. All but one, Moderna (MRNA), is an AI play. Of the seven standouts, Intel and Marvell are arguably actionable. Dell and Western Digital stock are close to entries.
Even given that memory plays are leading a hot AI rally, Sandisk stock's performance is stunning, with a massive 857.8% gain through 2026. But that looks positively mild compared to Sandisk earnings growth of 644% and 7,903% in the last two quarters, with 11,500% seen for the just-ended June quarter.
Since hitting a record 2,354.39 on June 22, SNDK stock has whipsawed up and down, but continued to hold the 21-day line.
Micron stock has quadrupled this year, up 304.4%. Earnings have exploded 682% and 1,215% in the past two quarters, with the memory-chip giant last week guiding sharply higher.
2 months ago
Moderna (MRNA) shares rallied on June 26 after the company detailed its future beyond COVID-19 at its highly anticipated Science Day event. Shares are continuing their upward trend today.
As investors cheered the positive updates, MRNA's relative strength index (RSI) climbed into the early 70s, indicating the stock may now be ripe for profit-taking.
Billionaire Mark Cuban Asks If AI 'Collapses' And Data Centers Turn Into 'Chuck E Cheeses,' Would That 'Create A Revival Of Jobs?'
As Trump Doubles Down on Quantum Computing, This Is the Top-Performing Stock to Buy YTD
Why Verizon, AT&T, and T-Mobile Should Be Terrified of Elon Musk's Next Move
As investors cheered the positive updates, MRNA's relative strength index (RSI) climbed into the early 70s, indicating the stock may now be ripe for profit-taking.
Billionaire Mark Cuban Asks If AI 'Collapses' And Data Centers Turn Into 'Chuck E Cheeses,' Would That 'Create A Revival Of Jobs?'
As Trump Doubles Down on Quantum Computing, This Is the Top-Performing Stock to Buy YTD
Why Verizon, AT&T, and T-Mobile Should Be Terrified of Elon Musk's Next Move
9 months ago
Inside a lab in the French city of Orleans, scientists are testing out the limits of molecules in our body called messenger RNA -- best known for being used in Covid-19 vaccines -- in the hopes of finding a breakthrough treatment for a particularly deadly cancer.
Messenger RNA, or mRNA, are molecules that carry genetic information from the DNA in every cell in the body to create specific proteins.
"For cancer, this message will stimulate the patient's ability to effectively fight tumours," Dimitri Szymczak, project manager of French research institute INSERM's ART lab in Orleans, told AFP.
Messenger RNA, or mRNA, are molecules that carry genetic information from the DNA in every cell in the body to create specific proteins.
"For cancer, this message will stimulate the patient's ability to effectively fight tumours," Dimitri Szymczak, project manager of French research institute INSERM's ART lab in Orleans, told AFP.
